[Company Letterhead]




April  30,  1997




To  Our  Stockholders:

          On April 15, 1997, ResMed's Board of Directors adopted a stockholder
Rights  Plan  that  is intended to protect your interests in the event you and
ResMed  are  confronted  with  coercive  takeover  tactics.

          The  Plan provides for a dividend distribution of Rights to purchase
shares  of  a  newly  created series of ResMed Preferred Stock.  Under certain
circumstances,  the  Rights could become exercisable to purchase ResMed Common
Stock,  or  securities  of an acquiring entity, at one-half market value.  The
Rights  may  be exercised only if certain events occur.  You are now the owner
of one Right for each share of ResMed Common Stock you own.  The Plan has been
adopted  in  order  to  strengthen  the  ability  of the Board to protect your
interests.

          We  are  attaching a summary description that outlines the principal
features  of  the  Plan,  and we urge you to read the summary carefully.  This
letter  reviews  our  reasons  for  issuing  the  Rights.

          NO ACTION BY STOCKHOLDERS IS REQUIRED OR PERMITTED AT THIS TIME, AND
NO  MONEY  SHOULD  BE SENT TO RESMED.  THE RIGHTS WILL AUTOMATICALLY ATTACH TO
THE SHARES OF COMMON STOCK YOU HOLD AND WILL TRADE WITH THEM.  SEPARATE RIGHTS
CERTIFICATES  WILL  BE SENT TO STOCKHOLDERS ONLY IF A PERSON OR GROUP ACQUIRES
15%  OR  MORE OF RESMED'S OUTSTANDING COMMON STOCK OR MAKES A TENDER OFFER FOR
15% OR MORE OF THE COMMON STOCK. RESMED COMMON STOCK CERTIFICATES ISSUED AFTER
APRIL  30,  1997  WILL CONTAIN A REFERENCE TO THE RIGHTS PLAN, BUT THERE IS NO
NEED  TO  SEND  IN  YOUR  CERTIFICATES  TO  HAVE  THIS  REFERENCE  ADDED.

          The  Rights  are  not  being distributed in response to any specific
effort  to acquire control of the Company.  The Rights are designed to protect
stockholders  in  the  event of an unsolicited attempt to acquire the Company,
including  through  an  accumulation  of  Common  Stock  in the open market, a
partial,  two-tier  or  inadequate  tender  offer  that  does  not  treat  all
stockholders  equally  and  other  abusive takeover tactics which the Board of
Directors  believes  are  not  in  the  best interests of stockholders.  These
tactics  unfairly  pressure stockholders, squeeze them out of their investment
without  giving  them  any  real  choice and deprive them of the full value of
their  Common  Stock.    We  consider  these  Rights to be a valuable means of
protecting  both your right to retain your equity investment in ResMed and the
full  value  of  that investment, while not foreclosing a fair acquisition bid
for  the  Company.

          The Rights are not intended to prevent a takeover of ResMed and will
not  do  so.    They  are  designed to deal with the possibility of unilateral
actions  by  hostile  acquirors  that could deprive the Board of Directors and
stockholders  of  ResMed  of  their  ability to determine ResMed's destiny and
obtain  the  highest  price  for  their  Common  Stock.



          Adoption  of  the  Plan  should not by itself affect any prospective
acquiror  who is willing to make an all-cash offer at a full and fair price or
who  is  willing to negotiate with the Company's Board of Directors.  The Plan
certainly  will  not  interfere  with  a  merger or other business combination
transaction  approved  by  the  Board  of  Directors.

          The  issuance  of the Rights has no dilutive effect, will not affect
reported  earnings  per  share  and  is not taxable to the Company or to you. 
Stockholders may, under certain circumstances, recognize taxable income if the
Rights  become  exercisable.

          Our  overriding objective is to continue building value for ResMed's
stockholders,  and  we  feel  that  the  Plan  will  assist  in  that  effort.


                              Sincerely,



                              /S/  Dr.  PETER  FARRELL
                              Dr.  Peter  C.  Farrell
                              President  and  Chief  Executive  Officer

- -2-

     SUMMARY  OF  RIGHTS  TO  PURCHASE
     PREFERRED  SHARES

          On April 15, 1997, the Board of Directors of ResMed Corporation (the
"Company")  declared a dividend of one Right for each share of common stock,
$.004  par  value  (the  "Common Shares"), of the Company outstanding at the
close  of  business  on  April 30, 1997 (the "Record Date").  As long as the
Rights  are  attached  to  the Common Shares, the Company will issue one Right
(subject  to  adjustment)  with  each new Common Share so that all such shares
will  have  attached  Rights.    When exercisable, each Right will entitle the
registered holder to purchase from the Company one one-hundredth of a share of
Series  A Junior Participating Preferred Stock (the "Preferred Shares") at a
price  of  $80.00  per  one  one-hundredth  of  a  Preferred Share, subject to
adjustment  (the "Purchase Price").  The description and terms of the Rights
are  set  forth in a Rights Agreement, dated as of April 23, 1997, as the same
may  be  amended  from  time  to  time (the "Rights Agreement"), between the
Company  and  American  Stock  Transfer  & Trust Company, as Rights Agent (the
"Rights  Agent").

          Until  the  earlier to occur of (i) ten (10) days following a public
announcement  that  a  person or group of affiliated or associated persons (an
"Acquiring  Person")  has  acquired,  or  obtained  the  right  to  acquire,
beneficial ownership of 15% or more of the Common Shares or (ii) ten (10) days
following  the  commencement  or announcement of an intention to make a tender
offer  or  exchange  offer  the  consummation  of  which  would  result in the
beneficial owner-ship by a person or group of 15% or more of the Common Shares
(the  earlier  of (i) and (ii) being called the "Distribution Date," whether
or  not  either such date occurs prior to the Record Date), the Rights will be
evidenced, with respect to any of the Common Share certificates outstanding as
of  the  Record Date, by such Common Share certificate together with a copy of
this  Summary  of  Rights.

          The  Rights Agreement provides that the Board of Directors, with the
concurrence  of a majority of the Continuing Directors (as defined below), may
postpone  the  Distribution  Date  and  that, until the Distribution Date, the
Rights  will  be  transferred with and only with the Common Shares.  Until the
Distribution  Date  (or  earlier  redemption or expiration of the Rights), new
Common  Share  certificates  issued  after the close of business on the Record
Date  upon  transfer  or  new  issuance  of  the  Common Shares will contain a
notation  incorporating  the  Rights  Agreement  by  reference.    Until  the
Distribution  Date (or earlier redemption, exchange, termination or expiration
of  the  Rights),  the  surrender  for transfer of any certificates for Common
Shares, with or without a copy of this Summary of Rights, will also constitute
the  transfer  of  the Rights associated with the Common Shares represented by
such  certificate.    As  soon as practicable following the Distribution Date,
separate  certificates  evidencing the Rights ("Right Certificates") will be
mailed  to  holders of record of the Common Shares as of the close of business
on  the  Distribution  Date  and  such  separate Right Certificates alone will
evidence  the  Rights.

          The  Rights  are  not  exercisable until the Distribution Date.  The
Rights will expire on April 30, 2007, subject to the Company's right to extend
such  date  (the  "Final  Expiration  Date"),  unless  earlier  redeemed  or
exchanged  by  the  Company  or  terminated.

- -3-


          Each Preferred Share purchasable upon exercise of the Rights will be
entitled  to  a  minimum  preferential quarterly dividend payment of $1.00 per
share but will be entitled to an aggregate dividend of 100 times the dividend,
if  any,  declared per Common Share.  In the event of liquidation, the holders
of the Preferred Shares will be entitled to a minimum preferential liquidation
payment  of $100 per share but will be entitled to an aggregate payment of 100
times  the  payment made per Common Share.  Each Preferred Share will have 100
votes and will vote together with the Common Shares.  Finally, in the event of
any  merger,  consolidation  or  other  transaction in which Common Shares are
exchanged,  each  Preferred  Share  will  be entitled to receive 100 times the
amount  received  per  Common  Share.  These rights are protected by customary
antidilution  provisions.    Because  of  the  nature of the Preferred Share's
dividend,  liquidation  and voting rights, the value of one one-hundredth of a
Preferred Share purchasable upon exercise of each Right should approximate the
value  of  one  Common  Share.

          The  Purchase  Price  payable, and the number of Preferred Shares or
other securities or property issuable, upon exercise of the Rights are subject
to  adjustment  from  time  to  time to prevent dilution (i) in the event of a
stock  dividend  on,  or a subdivision, combination or reclassification of the
Preferred  Shares,  (ii)  upon the grant to holders of the Preferred Shares of
certain  rights  or  warrants to subscribe for or purchase Preferred Shares or
convertible  securities at less than the current market price of the Preferred
Shares  or  (iii)  upon the distribution to holders of the Preferred Shares of
evidences  of  indebtedness,  cash,  securities  or  assets (excluding regular
periodic  cash  dividends  at  a rate not in excess of 125% of the rate of the
last  regular  periodic  cash  dividend  theretofore  paid or, in case regular
periodic  cash  dividends  have  not  theretofore  been paid, at a rate not in
excess  of 50% of the average net income per share of the Company for the four
quarters ended immediately prior to the payment of such dividend, or dividends
payable in Preferred Shares (which dividends will be subject to the adjustment
described  in  clause (i) above)) or of subscription rights or warrants (other
than  those  referred  to  above).

          In  the  event  that  a  Person  becomes an Acquiring Person (except
pursuant  to certain cash offers for all outstanding Common Shares approved by
the  Board)  or if the Company were the surviving corporation in a merger with
an  Acquiring  Person or any affiliate or associate of an Acquiring Person and
the Common Shares were not changed or exchanged, each holder of a Right, other
than  Rights  that  are  or  were  acquired  or  beneficially owned by the 15%
stockholder  (which  Rights will thereafter be void), will thereafter have the
right  to  receive  upon exercise that number of Common Shares having a market
value of two times the then current Purchase Price of the Right.  With certain
exceptions,  in  the event that the Company were acquired in a merger or other
business  combination  transaction  or  more than 50% of its assets or earning
power were sold, proper provision shall be made so that each holder of a Right
shall  thereafter  have the right to receive, upon the exercise thereof at the
then  current  Purchase  Price  of  the Right, that number of shares of common
stock  of  the  acquiring  company which at the time of such transaction would
have a market value of two times the then current Purchase Price of the Right.

          At  any time after a Person becomes an Acquiring Person and prior to
the  acquisition  by  such  Acquiring Person of 50% or more of the outstanding
Common  Shares,  the  Board  of Directors may cause the Company to acquire the
Rights  (other  than  Rights  owned  by  an Acquiring Person which have become
void),  in  whole  or  in  part,  in exchange for that number of Common Shares
having  an aggregate value equal to the Spread (the excess of the value of the
Common  Shares  issuable  upon  exercise  of a Right after a Person becomes an
Acquiring  Person  over the Purchase Price) per Right (subject to adjustment).

- -4-


          No  adjustment  in  the  Purchase  Price  will  be  required  until
cumulative  adjustments  require an adjustment of at least 1% in such Purchase
Price.  No  fractional shares will be issued and in lieu thereof, a payment in
cash  will  be  made  based on the market price of the Preferred Shares on the
last  trading  date  prior  to  the  date  of  exercise.

          The  Rights may be redeemed in whole, but not in part, at a price of
$.01  per  Right  (the  "Redemption Price") by the Board of Directors at any
time  prior to the close of business on the tenth day following the first date
of  public  announcement  that  a  Person has become an Acquiring Person.  The
Board  of  Directors,  with  the  concurrence  of a majority of the Continuing
Directors  (as  defined  below), may extend the period during which the Rights
are redeemable beyond the ten (10) days following the public announcement that
a  Person  has  become  an  Acquiring Person.  Under certain circumstances set
forth  in  the  Rights  Agreement,  the  decision  to redeem shall require the
concurrence  of  a majority of the Continuing Directors.  Immediately upon the
action of the Board of Directors of the Company electing to redeem the Rights,
the  Company  shall  make an announcement thereof, and upon such election, the
right  to exercise the Rights will terminate and the only right of the holders
of  Rights  will  be  to  receive  the  Redemption  Price.

          The  term  "Continuing Directors" means any member of the Board of
Directors  of the Company who was a member of the Board prior to the time that
any  Person  becomes  an  Acquiring Person, and any person who is subsequently
elected  to  the Board if such person is recommended or approved by a majority
of the Continuing Directors.  Continuing Directors do not include an Acquiring
Person,  or  an  affiliate  or  associate  of  an  Acquiring  Person,  or  any
representative  of  the  foregoing.

          Until  a  Right is exercised, the holder thereof, as such, will have
no  rights  as  a  stockholder  of  the  Company  beyond  those as an existing
stockholder,  including,  without  limitation, the right to vote or to receive
dividends.

           Any of the provisions of the Rights Agreement may be amended by the
Board  of  Directors of the Company prior to the Distribution Date.  After the
Distribution  Date,  the  Company and the Rights Agent may amend or supplement
the Rights Agreement without the approval of any holders of Right Certificates
to  cure  any  ambiguity,  to  correct  or  supplement any provision contained
therein  which  may  be  defective  or  inconsistent with any other provisions
therein, to shorten or lengthen any time period under the Rights Agreement (so
long  as,  under  certain  circumstances,  a  majority of Continuing Directors
approve  such  shortening  or  lengthening) or so long as the interests of the
holders  of Right Certificates (other than an Acquiring Person or an affiliate
or  associate  of  an Acquiring Person) are not adversely affected thereby, to
make any other provisions in regard to matters or questions arising thereunder
which  the  Company  and  the  Rights  Agent  may deem necessary or desirable,
including but not limited to extending the Final Expiration Date.  The Company
may  at  any time prior to such time as any Person becomes an Acquiring Person
amend the Rights Agreement to lower the thresholds described above to not less
than  the greater of (i) any percentage greater than the largest percentage of
the  outstanding  Common  Shares  then known by the Company to be beneficially
owned by any person or group of affiliated or associated persons and (ii) 10%.

          A  copy  of  the Rights Agreement has been filed with the Securities
and Exchange Commission as an Exhibit to a Registration Statement on Form 8-A.
 A copy of the Rights Agreement is available free of charge from the Company. 
This  summary description of the Rights does not purport to be complete and is
qualified  in  its  entirety  by  reference  to the Rights Agreement, which is
incorporated  herein  by  reference.

- -5-